| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 270.8 | 240.0 | 216.5 |
| Other income | 3.6 | 4.2 | 3.0 |
| Total income | 274.4 | 244.2 | 219.6 |
| Profit before exceptional items & tax | 77.8 | 67.6 | 62.3 |
| Exceptional items | -45.0 | 0.0 | 0.0 |
| Profit before tax | 33.6 | 68.3 | 62.6 |
| Net profit | 15.2 | 51.3 | 47.8 |
| Operating margin | 12.2% | 28.0% | 28.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -68.20% |
|---|---|
| Net profit, quarter on quarter | -70.40% |
| Revenue, year on year | +25.10% |
| Operating profit, year on year | +25.10% |
| Operating profit, quarter on quarter | +17.00% |
NSE results filing, NSE: THYROCARE. Figures extracted from the filing.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹514.95
- Market cap
- ₹8,196 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 46.5×Sector 52.0×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹270.8 Cr (+25.1%), EBITDA ₹89.3 Cr (33.0% margin), PAT before exceptions ₹60.2 Cr (+25.7%). Debt-free; NHL radiology divestment pending.
Thyrocare Technologies Results Update
Thyrocare Technologies reported Q2FY27 consolidated revenue of Rs 270.8 Cr, up 25.1% YoY, with PAT before exceptions of Rs 60.2 Cr. The press release also notes a Rs 45 Cr non-cash NHL impairment tied to a proposed divestment.
Thyrocare Technologies Board Meeting Date
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies Other Announcement
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies initiated a postal ballot for two resolutions: purchasing property from its subsidiary, Nueclear Healthcare, and selling its investment in Nueclear Healthcare.
Thyrocare Technologies Annual General Meeting
Thyrocare seeks shareholder approval via postal ballot for the purchase of land and building and the divestment of its subsidiary, Nueclear Healthcare Limited.
- Value
- ₹162.0 Cr